Novanta Inc.

Novanta Inc. (NOVT) Market Cap

Novanta Inc. has a market capitalization of $5.08B.

Price: $142.55

3.64 (2.62%)

Market Cap: 5.08B

NASDAQ · time unavailable

CEO: Matthijs Glastra

Sector: Technology

Industry: Hardware, Equipment & Parts

IPO Date: 1999-03-24

Website: https://www.novanta.com

Novanta Inc. (NOVT) - Company Information

Market Cap: 5.08B|Sector: Technology

Company Profile

Operating globally, Novanta Inc. and its affiliated companies specialize in the development, production, and distribution of advanced photonics, vision, and precision motion components and sub-assemblies. These highly engineered solutions are supplied to Original Equipment Manufacturers (OEMs) across the medical and industrial sectors. Within its Photonics division, Novanta provides a suite of laser-driven technologies. These encompass systems for laser scanning, beam manipulation, and various laser types such as CO2, solid-state, ultrafast, and optical light engines. Their applications span critical areas like industrial manufacturing, precision measurement (metrology), advanced imaging in healthcare and biological research, DNA sequencing, and specialized medical laser treatments. The Vision segment delivers an array of medical-grade innovations. This portfolio comprises instruments like medical insufflators, pumps, and their associated consumables, alongside comprehensive visualization tools. It also features wireless communication systems, video recording devices, and integration platforms designed for operating theaters. Further offerings include optical data acquisition, machine vision systems, radio frequency identification (RFID) solutions, thermal recording devices, spectrometry equipment, and integrated touchscreen displays. Furthermore, the Precision Motion division specializes in supplying components such as optical and inductive encoders, high-precision motors, servo drives, and complete motion control systems. This segment also delivers integrated stepper motors, sophisticated robotic end-effectors, air bearings, and air bearing spindles. Novanta distributes its extensive product lines through various channels, including its dedicated direct sales team, value-added resellers, distribution partners, and system integrators. These offerings are available under well-known brand names such as Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind. Founded in 1968, the company operated as GSI Group, Inc. until its rebranding to Novanta Inc. in May 2016. Its corporate headquarters are located in Bedford, Massachusetts.

Analyst Sentiment

92%
Strong Buy

From 3 Active Polls

1Y Forecast: $180.00

▲ +26.3% Potential Upside

Consensus Target Metrics

Low Bound

$180

Median

$180

High Bound

$180

Average

$180

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$180.00
▲ +26.27% Upside
Low Target
$180.00
26% Risk
Median Target
$180.00
26% Mid
High Target
$180.00
26% Max
Consensus
Buy
2 / 3 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MApr 3, 2026Dec 31, 2025Sep 26, 2025Jun 27, 2025Mar 28, 2025Dec 31, 2024Sep 27, 2024Jun 28, 2024
Market Cap ($M)5,0764,7314,5503,6344,6834,6505,4976,3465,863
Enterprise Value ($M)4,9784,6334,5114,0505,0864,9865,8546,7676,302
Price to Earnings Ratio (P/E)101.8256.2764.6784.19270.8354.6983.0383.24107.31
Price/Earnings-to-Growth Ratio (PEG)15.2529.9082.2622.9950.08
Price to Sales Ratio (P/S)5.0518.3617.6114.6619.4319.9323.0925.9624.86
Price to Book Ratio (P/B)4.403.613.464.535.846.047.378.558.35
Price to Free Cash Flow Ratio (P/FCF)75.54102.47886.39862.71400.79169.7192.67326.00162.15
Enterprise Value to Sales (EV/Sales)17.9817.4616.3421.1021.3724.5927.6926.72
Enterprise Value to EBITDA (EV/EBITDA)33.24109.38105.50108.04187.10109.29123.35137.52148.72
Debt to Equity Ratio-0.660.220.260.630.640.570.630.690.77

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 NOVANTA INC (NOVT) — Investment Overview

🧩 Business Model Overview

NOVANTA designs and manufactures precision-engineered subsystems used in advanced industrial and scientific equipment. The value chain centers on (1) application-specific engineering, (2) production of high-precision components and modules (often involving optics, sensors, actuators, and motion control), and (3) integration into customer platforms such as semiconductor manufacturing tools, automation systems, and metrology/inspection workflows. Customers typically qualify these subsystems through extensive performance testing and then deploy them as part of a larger installed system, creating a long-term service and replacement cycle.

💰 Revenue Streams & Monetisation Model

Revenue is primarily product-led, with a meaningful recurring component coming from ongoing service, support, and lifecycle needs after system qualification. Monetisation drivers include (1) the ability to engineer differentiated solutions rather than selling commodity components, and (2) maintaining service relationships with customers that already run NOVANTA-enabled equipment. Margin performance tends to be supported by higher-value engineered content, strong gross margin discipline inherent to precision manufacturing, and operating leverage as demand pulls through factory utilization and supply chain execution.

🧠 Competitive Advantages & Market Positioning

Primary moat: Switching costs via qualification + installed base. Competitors can offer functionally similar parts at the component level, but replacing a qualified subsystem in a production-grade environment is costly and risky. Customers face downtime, re-qualification, system performance verification, and engineering effort to ensure process stability. Over time, the installed base and the application-specific know-how embedded in the solution create high practical switching costs.

Secondary moat: Intangible assets in precision engineering and application expertise. NOVANTA’s differentiation is reinforced by engineering capabilities (tolerances, calibration, optical/mechatronic integration), manufacturing quality systems, and deep customer application understanding—assets that are difficult to replicate quickly without significant time, investment, and validation.

  • Competitive benchmarking:
  • Coherent (photonics and lasers): broader photonics exposure, often competing at the component/optics layer; NOVANTA’s positioning is more aligned with engineered subsystems and integrated precision platforms across automation and scientific equipment.
  • Aerotech (precision motion control): strong in motion solutions; NOVANTA typically competes with a wider precision portfolio that can address integrated motion/optics/sensing needs within customer systems.
  • Cognex (machine vision): strong in vision hardware/software; NOVANTA’s focus is more on precision optical/mechatronic subsystems used in demanding industrial and technical instrumentation contexts, where integration and qualified performance are critical.

NOVANTA’s industry focus spans high-spec automation, semiconductor-related workflows, and scientific/inspection use cases. This contrasts with rivals that may be more concentrated in one end-market or one component layer, leaving NOVANTA better positioned where system qualification and precision performance matter more than substitutable general-purpose hardware.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, the growth profile is tied to persistent capital spending themes that expand the need for precision automation and high-throughput inspection:

  • Semiconductor and electronics complexity: As devices scale and packaging/interconnect complexity rises, equipment requires improved precision, stability, and measurement/inspection capability—raising demand for qualified subsystems.
  • Industrial automation and quality control: Labor constraints and the need for yield improvement support more automation and more frequent inspection, increasing penetration of precision motion, sensing, and optical subcomponents.
  • Metrology and advanced inspection: Tighter tolerances drive demand for equipment that can measure and verify performance reliably, supporting sustained replacement and expansion cycles after qualification.
  • Lifecycle expansion: Once deployed, customers tend to extend system upgrades and maintenance using the incumbent ecosystem, supporting revenue continuity through service and replacement demand.

The TAM expands not only through unit growth in automation equipment, but also through higher “precision content” per tool and per production line as tolerances tighten and inspection requirements broaden.

⚠ Risk Factors to Monitor

  • End-market capex cyclicality: Semiconductor equipment cycles and industrial automation spending can swing with demand, affecting order pacing.
  • Competition and qualification barriers: Even with switching costs, competitors that successfully clear performance and qualification hurdles can win new programs.
  • Technology and platform shifts: Architectural changes in customer tool design (including alternative sensing/actuation approaches) can alter performance requirements.
  • Manufacturing execution and supply chain concentration: Precision manufacturing is sensitive to component availability, lead times, and quality controls; disruptions can impact delivery performance.
  • Integration risk from acquisitions: If growth is supported by inorganic activity, integration of products, quality systems, and commercial structures can influence long-run margin outcomes.

📊 Valuation & Market View

Equity markets typically value NOVANTA and similar industrial precision businesses using EV/EBITDA and growth-oriented multiples that reward (1) margin durability, (2) operating leverage potential from scale, and (3) evidence of durable demand in end markets with long equipment qualification cycles. Price-to-sales frameworks can also be used when investors emphasize engineered content and recurring service attachment, but the multiple usually becomes more sensitive to margin trajectory, backlog/visibility signals, and confidence in end-market conversion rather than purely top-line growth.

🔍 Investment Takeaway

NOVANTA’s long-term investment case rests on precision-engineered differentiation backed by high practical switching costs stemming from qualification, installed-base familiarity, and application integration. As semiconductor and industrial systems demand tighter tolerances and higher inspection/automation intensity, NOVANTA’s engineered subsystem portfolio is positioned to capture share through program wins and lifecycle demand—while investors should monitor end-market cyclicality, qualification dynamics, and execution risk in manufacturing and integration.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for NOVT.

seekingalpha.com2026-07-31

Conestoga SMid Cap Composite Q2 2026 Portfolio Review

West Pharmaceuticals stock moved higher following another quarter of broad-based growth, driven by continued demand for high-value biologics packaging and proprietary delivery components. Tyler Technologies underperformed during the quarter despite delivering solid financial results that met management's guidance. We were attracted to Knowles' accelerating organic growth, expanding margins, and exposure to several attractive long-term secular trends.

defenseworld.net2026-07-30

Analyzing Vicor (NASDAQ:VICR) & Novanta (NASDAQ:NOVT)

Novanta (NASDAQ: NOVT - Get Free Report) and Vicor (NASDAQ: VICR - Get Free Report) are both mid-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings. Analyst Recommendations This is a breakdown of

zacks.com2026-07-29

Will Novanta (NOVT) Beat Estimates Again in Its Next Earnings Report?

Novanta (NOVT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com2026-07-29

Novanta (NOVT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Novanta (NOVT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

defenseworld.net2026-07-28

American Capital Management Inc. Has $44.16 Million Stake in Novanta Inc. $NOVT

American Capital Management Inc. lowered its position in shares of Novanta Inc. (NASDAQ: NOVT) by 2.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 373,874 shares of the technology company's stock after selling 7,992 shares during the period. Novanta

businesswire.com2026-07-27

Novanta Completes Acquisition of Riverpoint Medical

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today announced that it has completed the acquisition of Riverpoint Medical (“Riverpoint Medical” or “Riverpoint”) from Arlington Capital Partners. Riverpoint is a category leader in high-growth minimally invasive surgical consumables, including advanced surgical fibers and related technologies for sports medicine, trauma and.

businesswire.com2026-07-14

Novanta Inc. Announces Schedule of Second Quarter 2026 Earnings Release and Conference Call

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2026 results after the close of U.S. financial markets on Wednesday, August 5, 2026. The Company will host a conference call on Thursday, August 6, 2026, at 8:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the con.

zacks.com2026-06-25

Novanta (NOVT) Upgraded to Buy: What Does It Mean for the Stock?

Novanta (NOVT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

businesswire.com2026-06-22

Novanta to Present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, and Chuck Ravetto, Chief Operating Officer, are scheduled to present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026, in White Plains, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical,.

zacks.com2026-06-17

Novanta (NOVT) is a Great Momentum Stock: Should You Buy?

Does Novanta (NOVT) have what it takes to be a top stock pick for momentum investors? Let's find out.

seekingalpha.com2026-06-10

Novanta Inc. (NOVT) M&A Call Transcript

Novanta Inc. (NOVT) M&A Call Transcript

businesswire.com2026-06-09

Novanta Inc. Announces $300 Million Private Placement

BOSTON--(BUSINESS WIRE)--Novanta Inc. ("Novanta" or the “Company”) announced today that it has entered into a securities purchase agreement for a private placement of the Company's common shares (“Common Shares”) to institutional and other accredited investors that is expected to result in gross proceeds of approximately $300 million to the Company, before placement agent fees and offering expenses. Pursuant to the terms of the securities purchase agreement, the investors agreed to purchase an.

businesswire.com2026-06-09

Novanta Inc. Announces Acquisition of Riverpoint Medical

BOSTON--(BUSINESS WIRE)--Novanta Inc. (NASDAQ: NOVT) (“Novanta” or the “Company”), a trusted technology partner to leading global medical and industrial original equipment manufacturers (OEMs), today announced that it has entered into a definitive agreement to acquire Riverpoint Medical (“Riverpoint Medical” or “Riverpoint”), a category leader in high-growth minimally invasive surgical consumables, from Arlington Capital Partners (“Arlington”), a Washington D.C.-area private investment firm. Un.

gurufocus.com2026-06-08

A Look at Novanta Inc (NOVT) After 5.1% Gain -- GF Value $153.89 vs Price $164.34

On June 08, 2026, Novanta Inc (NOVT) shares rose 5.1% to $164.34. This increase comes amid a strong year-to-date performance, with shares up 38.1%, and a signif

gurufocus.com2026-05-22

A Look at Novanta Inc (NOVT) After 3.1% Gain -- GF Value $154.22 vs Price $159.70

On May 22, 2026, Novanta Inc (NOVT) shares rose 3.1% to $159.70, reflecting a positive price movement amid a strong performance over the past month and year. Th

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-04-03

"NOVT reported Q1 2026 revenue of $257.7M and net income of $21.1M (EPS: $0.52). Revenue was up +1.3% QoQ (vs. $258.3M in Q4 2025) and +10.3% YoY (vs. $233.4M in Q1 2025). Net income increased +20.8% QoQ (from $17.5M) and +−0.0% YoY (essentially flat vs. $21.2M in Q1 2025). Margins weakened over the quarter: net margin contracted to 8.2% from 6.8% in Q4 (improved QoQ) but was slightly below the earlier Q1 2025 level (9.1%), while operating margin rose to 10.7% from 18.4% in Q4—indicating a notable reversal in operating profitability. Balance sheet resilience remains strong: total assets were $1.80B with equity at $1.31B. Cash and cash equivalents were $388.8M, and net debt improved markedly to -$110.1M (net cash) from -$39.3M at Q4 2025, reflecting balance sheet strengthening and/or deleveraging. Cash flow quality looks solid in the quarter with operating cash flow of $51.6M and free cash flow of $47.5M. Shareholder returns are supported by the stock’s momentum (1y change +13.0%; 6m +20.9%), but there is no evidence of a very strong >20% 1-year rally. No dividends were paid; repurchases occurred ($18.6M in Q1)."

Revenue Growth

Positive

Q1 2026 revenue of $257.7M grew +1.3% QoQ and +10.3% YoY, showing steady top-line expansion.

Profitability

Fair

Net margin was 8.2% in Q1 2026 vs 6.8% QoQ improvement, but down vs 9.1% YoY; operating margin signals volatility (10.7% in Q1 2026 vs 18.4% in Q4 2025). EPS was $0.52 vs $0.59 in Q1 2025 (YoY down).

Cash Flow Quality

Positive

Operating cash flow was $51.6M and free cash flow $47.5M in Q1 2026, supporting earnings with strong cash conversion for the quarter; no dividends (payout ratio 0).

Leverage & Balance Sheet

Good

Total equity held up at $1.31B and net debt improved to net cash (-$110.1M) from net cash (-$39.3M) in Q4 2025, indicating improved financial resilience.

Shareholder Returns

Fair

Capital appreciation is positive (1y +13.0%, 6m +20.9%) and Q1 included buybacks (-$18.4M), but no dividend yield and the 1-year momentum is below a >20% threshold.

Analyst Sentiment & Valuation

Fair

Consensus price target is $150 vs current price $128.85 (moderate upside). Valuation metrics remain rich (e.g., price-to-sales ~18x and high P/E), which tempers the score despite operational progress.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Novanta’s Q1 2026 shows strong demand and execution: bookings rose 37% YoY (book-to-bill 1.10) with revenue +10% reported (+3% organic) and broad-based double-digit bookings/revenue growth across segments. Profitability improved materially—adjusted EBITDA +14% YoY and margin expansion of +70 bps—alongside exceptional cash performance (operating cash flow +63% YoY; >200% cash conversion to net income). The main negative is gross margin timing: adjusted gross margin fell 60 bps YoY to 45.6%, driven by freight, tariff, and material cost inflation outpacing surcharges/repricing. Management is actively offsetting costs via pricing actions, backlog repricing, and two facility closures on track for Q2 to drive a gross margin step-up in H2. Guidance was reaffirmed on EBITDA and EPS ranges but raised on GAAP revenue ($1,040m–$1,055m). GenAI-related AI data center exposure is quantified at ~15% of revenue, expected to accelerate through the year.

AI IconGrowth Catalysts

  • Robotics & Automation: bookings up 50% YoY; new product revenue up >70% YoY; GenAI-driven tailwinds supporting precision robotics/warehouse automation
  • Precision Manufacturing: intelligent laser beam steering subsystems launched; AI data center application momentum; Precision Manufacturing returned to mid- to high-single-digit revenue growth
  • Advanced Surgery: next-generation insufflators driving double-digit growth; scalable medical consumables franchise (15% of revenue) growing at sustained double-digit rates
  • Precision Medicine: Keonn acquisition contributed to double-digit growth; life science exposure expected <10% of total revenue in 2026
  • GenAI data center-related applications: ~15% of total company revenue in Q1; grew ~20% YoY with expectation of accelerating growth through the year

Business Development

  • Joined NVIDIA Halos AI Systems Inspection Lab (March 2026), with management stating Novanta is the only servo drive manufacturer selected; certification validates safe AI-driven robotics integration
  • Assumed recurring design-in via OEM collaborative partnerships; exclusivity designed-in product relationships typically last up to a decade (no specific OEM names provided)

AI IconFinancial Highlights

  • Beat expectations: revenue +10% reported growth and +3% organic growth; bookings +37% YoY with book-to-bill 1.10
  • Profitability: adjusted EBITDA +14% YoY; adjusted EBITDA margin +70 bps YoY; adjusted diluted EPS +9% YoY
  • Cash flow strength: operating cash flow +63% YoY; cash conversion to net income >200% in Q1
  • Adjusted gross margin: 45.6% vs 46.0% in Q1 2025; down 60 bps YoY and roughly flat sequentially
  • Margin headwind explained: price/cost timing impact from higher freight, tariff costs, and material costs; rapid geopolitical-driven cost increases outpaced ability to surcharge/reprice
  • Tax: non-GAAP tax rate 19% vs 20% in Q1 2025; decrease due to jurisdictional mix of pretax income
  • EPS and headwinds: adjusted EPS $0.81, includes $0.03 headwind from temporary inflation/tariff impacts
  • Second quarter margin guidance: adjusted gross margins 45.5%–46.0% (flat to modestly ahead sequentially); expects improved second-half margins as surcharging, pricing, and cost actions fully take hold
  • Full-year guidance update: GAAP revenue $1,040m–$1,055m (raised range); adjusted EBITDA $245m–$250m; adjusted EPS $3.50–$3.65

AI IconCapital Funding

  • Share repurchases: purchased approximately $18m of company stock in Q1
  • Balance sheet: gross debt $249m; gross leverage ratio 1.1x; cash balance $389m; net debt negative $139m; net leverage ratio negative 0.6x (net cash position maintained)
  • Capital allocation: acquisitions remain top priority; buybacks continue opportunistically but are tempered by active acquisition pipeline (no total FY buyback authorization disclosed)

AI IconStrategy & Ops

  • Manufacturing foundation: two facility closures on track to complete in Q2; consolidating into fewer centers of manufacturing excellence to support a gross margin step-up in H2
  • Pricing/surcharging actions: implemented product price increases and updated all surcharges to reflect new tariff rates; working to reprice existing backlog
  • Risk management inventory: deliberate safety stock investments in electronic components, rare earth materials, and inventory tied to regional manufacturing routes to avoid part shortages
  • R&D/SG&A cost structure: R&D $23m (~9% of sales), down 1 point YoY; SG&A ex certain adjustments $51m (~20% of sales), flat as % of sales
  • Cash flow target: expects cash flow conversion to net income 100% or better as % of net income for Q2 and full year

AI IconMarket Outlook

  • Organic growth outlook: management expects organic growth to reach high single digits in Q2 and continue acceleration through back half absent deeper macro/geopolitical shift
  • Full-year 2026 organic growth: up to 6% organic (reported growth >7%) within raised GAAP revenue range
  • Q2 guidance: GAAP revenue $259m–$264m; organic growth 6%–8% and reported revenue growth up to 10%
  • Q2 bookings→revenue lag commentary: management reiterated typical 2–3 quarter lag from bookings to revenue

AI IconRisks & Headwinds

  • Gross margin pressure in Q1: freight, tariff costs, and material cost inflation caused price/cost timing mismatch because costs shifted faster than customer surcharging and order repricing
  • Geopolitical and trade dynamics: management cited ongoing complexity affecting input costs and the ability to reprice backlog quickly
  • Tariff refund uncertainty: no benefit from potential U.S. government tariff refunds included in guidance; management views this as a risk buffer if implementation timing shifts
  • Order timing/cycle risk: management noted early-year customer preference for full-year orders and typical bookings-to-revenue lag (2–3 quarters), requiring disciplined guidance updates

Q&A: Analyst Interest

  • Topic: GenAI data center exposure quantification and what it includes: Management clarified that the ~15% of sales, ~20% YoY GenAI-driven portion is a collective spanning Precision Manufacturing and Robotics & Automation applications. It includes DUV/EUV lithography, GPU drilling, probe card production, metrology for 2-nanometer nodes, and precision robotics tailored to advanced wafer fab/advanced industrial uses.
  • Topic: NVIDIA Halos AI Systems Inspection Lab and commercialization timing: Management said Novanta is (to its knowledge) the only servo drive manufacturer selected via a rigorous certification process. The lab certification reduces OEM sub-testing friction, supporting prototype orders. They temper expectations but expect more meaningful impact in 2027 as adoption matures through the cycle.
  • Topic: Reconciling 37% bookings growth vs modest organic revenue growth and order timing: Management stated the majority of orders ship within the next 12 months and emphasized Q1 dynamics: year-over-year against a lower prior-year base, some customers placing full-year orders in Q1, and a typical 2–3 quarter bookings-to-revenue lag. Discipline delayed broader upward revisions until one revenue/profit quarter clears.

Sentiment: MIXED

Note: This summary was synthesized by AI from the NOVT Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for NOVT.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (NOVT)

© 2026 Stock Market Info — Novanta Inc. (NOVT) Financial Profile